Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionToth Financial Advisory Corp
Latest Disclosed Ownership306 shares
Latest Disclosed Value $ 136,642
Toth Financial Advisory Corp reports 33.04% increase in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On April 16, 2026 - Toth Financial Advisory Corp filed a 13F-HR form disclosing ownership of 306 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $136,641 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 20, 2026 disclosing 230 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of 33.04% during the quarter. The current value of the position is $131,072 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-16 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 306 76 33.04 137 30.77 0.0150
2026-01-20 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 230 0 0.00 104 15.56 0.0113
2025-10-09 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 230 0 0.00 90 -11.76 0.0097
2025-07-14 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 230 0 0.00 102 -8.11 0.0119
2025-04-14 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 230 0 0.00 112 20.65 0.0134
2025-01-21 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 230 -1,320 -85.16 93 -87.22 0.0109
2024-10-21 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,550 1,450 1,450.00 721 1,465.22 0.0851
2024-07-16 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 100 0 0.00 47 12.20 0.0060
2024-04-16 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 100 0 0.00 42 2.50 0.0052
2024-01-26 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 100 0 0.00 41 17.65 0.0055
2023-10-12 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 100 0 0.00 35 -2.86 0.0053
2023-07-24 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 100 -39 -28.06 35 -18.60 0.0051
2023-04-24 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 139 39 39.00 44 53.57 0.0068
2023-01-24 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 100 0 0.00 29 -3.45 0.0047
2022-10-14 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 100 0 0.00 29 3.57 0.0052
2022-07-25 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 100 0 0.00 28 7.69 0.0049
2022-04-26 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 100 0 0.00 26 18.18 0.0039
2022-01-31 2021-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 100 82 455.56 22 633.33 0.0030
2021-10-20 2021-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 18 0 0.00 3 -25.00 0.0005
2021-07-26 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 18 0 0.00 4 0.00 0.0006
2021-04-20 2021-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 18 0 0.00 4 0.00 0.0006
2021-01-25 2020-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 18 -2,875 -99.38 4 -99.49 0.0007
2020-10-16 2020-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,893 -1,610 -35.75 787 -39.79 0.1511
2020-07-14 2020-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 4,503 443 10.91 1,307 35.30 0.2830
2020-04-20 2020-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 4,060 1,330 48.72 966 61.54 0.2790
2020-01-27 2019-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,730 2,730 598 0.1213
2019-07-17 2019-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 0 -1,642 -100.00 0 -100.00
2019-04-15 2019-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,642 1,642 302 0.0707
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.